Home » Newsletters » BioWorld Science

BioWorld Science

May 21, 2012

View Archived Issues

Data reported on effects of HSC gene therapy for metachromatic leukodystrophy

Sonic hedgehog pathway inhibitors disclosed by U.S. researchers

Teva Pharmaceutical Industries patents novel compounds for MS

Novel histone deacetylase inhibitors prepared by Georgia Tech Research Corp.

Promising results reported for first patients in phase I trial of VRX-007

In vivo studies show new therapeutic potential for CDDO-Me

Daclatasvir shows promise in difficult-to-treat populations

Alisporivir results in hepatitis C virus genotypes 1, 2 and 3 reported

Novel protease inhibitors for HIV patented

Monash University presents new antimicrobial peptides

Merz Pharma designs novel cognition-enhancing drugs

Novel AMPK activators designed by Roche

Anti-marinobufagenin antibody studied in salt-sensitive hypertension

Taisho updates pipeline progress for fiscal 2011

Shionogi reviews pipeline progress of fourth quarter of fiscal 2011

Janssen gains Japanese approval for anti-HIV agent

Agilent set to acquire leading cancer diagnostic company

ArQule and Daiichi Sankyo complete patient recruitment in phase III tivantinib study

Ocera obtains CE Mark for Zysa

Half of target patient population recruited in phase III tasquinimod study

ASLAN obtains global rights to Almirall's DHOdehase inhibitor

Pharmaxis submits NDA for Bronchitol

Helix BioPharma receives clearance for European phase III study in low-grade cervical lesions

MRC Technology and Queen Mary University of London enter multiple GPCR collaborations

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...